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Abstract 
 γδ T cells account for a large fraction of human intestinal intraepithelial lymphocytes (IELs) 
endowed with potent anti-tumor activities. However, little is known about their origin, phenotype and 
clinical relevance in colorectal cancer (CRC). To determine γδ IEL gut-specificity, homing and 
functions, γδ T cells were purified from human healthy blood, lymph nodes, liver, skin, intestine either 
disease-free or affected by CRC or generated from thymic precursors. The constitutive expression of 
NKp46 specifically identifies a new subset of cytotoxic Vδ1 T cells representing the largest fraction of 
gut-resident IELs. The ontogeny and gut-tropism of NKp46pos/Vδ1 IELs depends both on distinctive 
features of Vδ1 thymic precursors and gut-environmental factors. Either the constitutive presence of 
NKp46 on tissue-resident Vδ1 intestinal IELs or its induced-expression on IL-2/IL-15 activated Vδ1 
thymocytes are associated with anti-tumor functions. Higher frequencies of NKp46pos/Vδ1 IELs in 
tumor-free specimens from CRC patients correlate with a lower risk of developing metastatic III/IV 
disease stages. Additionally, our in vitro settings reproducing CRC tumor-microenvironment inhibited 
the expansion of NKp46pos/Vδ1 cells from activated thymic precursors. These results parallel the very 
low frequencies of NKp46pos/Vδ1 IELs able to infiltrate CRC, thus providing new insights to either 
follow-up cancer progression or develop novel adoptive cellular therapies.  
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Introduction 
 The gastrointestinal (GI) tract is considered the largest immunological organ in the human body 
with both circulating and tissue-specific immune cells either organized in several structures of the 
lamina propria (LP) or resident within the epithelium. The synergic interactions of immune cells with 
both epithelial cells and microbiota shape innate and adaptive immune responses, set up the threshold 
between immune tolerance and effector-functions and also balance the efficacy of checkpoint blockade 
in cancer immunotherapy (1, 2). 
The human gut epithelium is home to large numbers of T cells expressing gamma delta (γδ) T 
cell receptors (TCR), which account for the main fraction of all intraepithelial lymphocytes (IELs) (3). 
While the exact functions of γδ IELs remain elusive, they have been suggested to control anti-
microbial defense, organ homeostasis and tissue damage repair (4, 5). Indeed, γδ T cell-deficient mice 
present abnormalities in gut epithelial morphology, reduced MHC class II expression by enterocytes 
and impaired mucosal IgA production (6, 7). Although γδ T cells originate from common thymic 
precursors alongside αβ T cells, they are considered innate-like lymphocytes for their rapid and non 
MHC-restricted effector responses such as cytotoxicity and secretion of type I cytokines (8). Human γδ 
T cells are broadly divided into two main Vδ1 and Vδ2 subsets based on their TCRδ-chain repertoire 
(9). Under homeostatic conditions, Vδ2 cells are mainly enriched in peripheral blood where they 
represent about 5% of all circulating T cells and recognize specifically microbial or stress-/ tumor-
induced “phosphoantigens” (8, 10-12). In contrast, Vδ1 cells are preferentially localized in peripheral 
tissues such as the gut, skin and liver. However, very little is known about their organ-specificity and 
local antigens/ligands recognition. 
Growing evidences confirmed the important role of γδ T lymphocytes in tumor immune-
surveillance and provided promising perspectives in cancer immunotherapy (13). Indeed, both Vδ1 
and Vδ2 subsets expanded from peripheral blood are endowed with high anti-tumor activities against 
hematological malignances and solid tumors in vivo and in vitro (14). Therefore, much effort has been 
made to improve blood γδ T cell-mediated tumor recognition and killing (15). In this context, we 
previously showed that the TCR stimulation in vitro induces a de novo expression of Natural 
Cytotoxic Receptors (NCRs) (mainly NKp30) on circulating Vδ1 T cells, thus remarkably increasing 
their anti-tumor effector functions (16). Hence, NCRs are no longer considered as specific Natural 
Killer (NK) cell activating receptors (aNKR) and are currently being implemented for developing 
novel adoptive cellular therapies against cancers (17, 18).  
In contrast to the peripheral blood γδ T cells that have received much attention, both phenotype 
and anti-tumor potentials as well as the mechanisms regulating the homeostasis of human tissue-
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resident γδ T cells are still largely unknown. Indeed, while mice share some common innate-like 
functions of human γδ T cells, they differ significantly in terms of TCR specificity and tissue 
specialization (19). Nonetheless, several studies reported that in different types of human cancers, 
including colorectal cancer (CRC), high frequencies of intra-tumoral γδ T cells represent one of most 
favorable prognostic markers in tumor clinical outcomes (20, 21). Hence, there is a pressing need to 
better characterize human tissue-resident γδ T lymphocytes in order to understand their impact in the 
physiopathology of cancer.  
The present study identifies a novel subset of gut-resident Vδ1 IELs naturally expressing high 
levels of NKp46. The presence of this NCR characterizes the largest subset of γδ T cells among 
intestinal IELs, a population that we could not detect in healthy human skin, lymph nodes, liver and 
not even in the gut of wild-type mice strains. NKp46pos/Vδ1 IELs share the same phenotypic and anti-
tumor effector-functions of NKp46pos/Vδ1 T cells generated from thymic precursors following 
activation with Interleukin (IL)-2 or IL-15, two cytokines highly enriched in gut microenvironment 
that confer to Vδ1 thymocytes a specific gut tropism. Low frequencies of NKp46pos/Vδ1 IEL subset in 
healthy gut specimens of patients affected by CRC are associated with a faster tumor progression and 
development of metastatic diseases, thus suggesting a protective role and a potential prognostic value 
of these tissue-resident innate-like lymphocytes in CRC. 
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Results 
Identification of a novel subset of NKp46pos γδ  intestinal intraepithelial T lymphocytes. 
 Human healthy colon specimens obtained from patients who underwent surgical resection for 
colorectal cancers (CRC) were located at the distal part (≥ 10 cm in length) of the removed tumor core 
and were considered “tumor-free/healthy” after a conventional macroscopic and microscopic 
examination by pathologists. Healthy gut specimens were processed to obtain intraepithelial 
lymphocytes (IELs) and lamina propria lymphocytes (LPLs) (Supplemental Figure 1A-C). As 
expected (22), the frequency of γδ T cells appeared to be significantly higher among IELs compared to 
both LPLs and Peripheral Blood Mononuclear Cells (PBMCs) (Figure 1A-B). Unlike circulating γδ T 
cells, both γδ IELs and LPLs presented high levels of the tissue-resident marker CD69 (23). The 
different location of intestinal γδ IELs and LPLs was also confirmed by specific high expression on the 
first subset and not on the second one of CD103, the main adhesion molecule involved in the specific 
retention of IELs in the epithelial layer (Figure 1C) (24). We also observed that γδ IELs are 
characterized by a significant higher expression of CD56 and CD8 compared to γδ LPLs, while 
expressing low surface levels of CD4. These phenotypic features of γδ IELs are also associated with 
low amounts of inhibitory NKRs (iNKRs) (i.e. NKG2A and KIRs) and high expression of aNKRs (i.e. 
NKG2C and NKG2D), thus suggesting that γδ IELs are endowed with a high cytolytic potential 
(Figure 1D). 
Circulating γδ T cells do not physiologically express NCRs (16).	  In contrast, we found that 
γδ IELs constitutively express high levels of NKp46, while their counterparts from LP showed a 
significant lower natural expression of this NCR. Although at a minor extent compared to NKp46, 
γδ IELs are also NKp44pos in contrast to γδ LPLs and PBMCs that have significantly lower surface 
levels of this NCR. No significant differences were observed for NKp30 surface levels between γδ T 
intestinal cells (both IELs and LPLs) and PBMCs (Figure 1E, Supplemental Figure 1D). The presence 
of NKp46pos γδ T cells in the IE compartment of human intestine was also confirmed by confocal 
microscopy (Supplemental Figure 1E).  
CD8pos γδ IELs had been first characterized as a subset of unconventional T cells expressing in 
their TCR complex the homodimer CD8αα that induces cell hypo-responsiveness/anergy (25). 
Another study later identified a novel population of high cytotoxic and immune-regulatory intestinal 
CD8pos γδ T cells carrying the heterodimer CD8αβ. This latter immuno-regulatory subset plays a key 
role in the homeostasis of Gut-Associated Lymphoid Tissue and in the pathogenesis of inflammatory 
bowel disease (26). Our results showed that, while the entire population of CD8pos γδ IELs express 
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significantly higher levels of α rather than β chain, the subset of NKp46pos/CD8pos γδ IELs co-
expresses similar levels of α and β chains in their CD8 receptor (Figure 1F).  
CD45pos/CD3pos IELs from healthy gut specimens were also analyzed by a dimensionality 
reduction method that used the t-Distributed Stochastic Neighbor Embedding (t-SNE) algorithm. Two 
different and separate clusters of NKp46neg (C1) NKp46pos (C2) γδ IELs were identified on the basis of 
population boundaries distinguishable on the polychromatic flow cytometry density plots (Figure 1G). 
The related heatmap showed that C1 and C2 are characterized by distinctive phenotypes with higher 
expression of NKp44, NKp30, CD8β, CD56, NKG2C and NKG2D and lower expression of inhibitory 
Killer Immunoglobin Receptors (KIRs) in NKp46pos γδ IELs compared to NKp46neg γδ IELs (Figure 
1H).  
Taken together, this first set of data indicates that the presence of NKp46 identifies a specific 
cluster of intestinal CD8 γδ IELs carrying the heterodimer CD8αβ and whose phenotype is likely 
associated with immune effector-functions (i.e. cytotoxicity and cytokine productions) rather than 
immune-tolerance. 
 
NKp46pos γδ  IELs are Vδ1 restricted and preferentially enriched in human intestine. 
 As expected (25), γδ IELs comprised higher proportions of Vδ1 T cells in contrast to their 
counterpart in the blood, known to be mainly Vδ2-restricted (8). A consistent fraction of γδ LPLs 
neither express Vδ1 nor Vδ2 chain, a phenomenon that we also observed within both IEL and PBMC 
compartments although at a lower extent (Figure 2A). Therefore, the intestinal LP compartment might 
be, together with human liver, another preferential tissue where other γδ T cell subsets, such as the 
Vδ3pos one, could reside (27). Interestingly, we found that NKp46 specifically identifies Vδ1 IELs, 
while Vδ2 IELs express significantly lower amounts of this NCR. NKp44 marks only a small fraction 
of γδ IELs with the Vδ1 subset expressing significantly higher levels of this NCR compared to the Vδ2 
population. Both Vδ1 and Vδ2 IELs express very low levels of NKp30 (Figure 2B-C).  
Vδ1 IELs are characterized by a CD4neg/CD8pos phenotype with high surface levels of CD56 
and NKG2D while expressing low amounts of NKG2A and KIRs. In contrast, Vδ2 IELs express 
significantly lower levels of CD8 and CD56 together with significantly higher amounts of NKG2A 
when compared with their Vδ1 counterpart (Figure 2D). We then purified IELs from matched healthy 
ileum and colon specimens from patients affected by Crohn’s disease and having undergone surgical 
gut resection. We found similar frequencies of Vδ1 and Vδ2 T IELs both in ileum and colon, with a 
higher percentage of Vδ1 compared to Vδ2 cells (Supplemental Figure 2A). Again, the NKp46 
expression in the ileum is mainly restricted on Vδ1 IELs in both anatomical sites without any 
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statistically significant differences between ileum and colon (Supplemental Figure 2B). These results 
indicate that NKp46pos/Vδ1 lymphocytes represent the largest and most ubiquitous γδ T cell population 
within the IEL compartment of both small and large intestine. 
We then determined the constitutive NCR expression on γδ T cells purified from other human 
healthy tissues known to be highly enriched of these innate-like T cells: skin, liver and lymph nodes 
(5, 28). Although skin and liver are predominantly enriched with the Vδ1 cell subset over the Vδ2 one, 
they do not express NCRs in both tissue sites. Similarly, also Vδ1 and Vδ2 T cells purified from 
lymph nodes are NKp46neg and NKp44neg, while a minor fraction of both subsets is NKp30pos 
(Supplemental Figure 3). 
Even though murine and human γδ T cells differ in several phenotypic features and tissue 
distribution, Vδ1 T cells have been shown to be more similar between the two species compared to 
their Vδ2 counterparts (19). Moreover, NKp46 is the only NCR to be phylogenetically conserved in 
mice and humans (29). Hence, we investigated whether human NKp46pos/Vδ1 IELs have an equivalent 
in the intestine of BALB/c and C57BL/6 mice strains. Although murine gut contains high frequencies 
of γδ T IELs, they do not express NKp46. Instead, tissue-resident NK cells from the same murine 
specimens express, as expected, detectable levels of this NCR and were used as internal positive 
controls of these experiments in mice (Supplemental Table 1 and Supplemental Figure 4). We also 
found that the degree of frequency of total γδ IELs and NKp46pos/Vδ1 IELs in the intestine is both age- 
and sex-independent (Supplemental Figure 5). 
 
Common features but distinct TCR repertoire of NKp46pos and NKp46neg IEL subsets. 
The repertoire of γδ TCR was analyzed via high-throughput sequencing of V(D)J-regions of 
either the γ-chain (TRG) or δ-chain (TRD) expressed on FACS-sorted Vδ1 NKp46pos and NKp46neg 
IELs.  The purity of all sorted samples was ≥ 95% (Supplemental Figure 6). Our data showed that the 
TRG repertoires of total NKp46pos and NKp46neg Vδ1 IELs is mainly represented by highly expanded 
Vγ9neg γδ T cell clones (Figure 3A). We also observed more recurrent usage of Vγ4pos sequences in the 
NKp46pos IEL subset among different individuals (Figure 3B). On the other hand, extended variability 
of Vγ chains with similar incidence of Vγ9pos and Vγ4pos sequences were presented in NKp46neg IELs. 
For TRD repertoires, we found a considerable fraction of Vδ2pos sequences within Vδ1 IELs (data not 
shown), a phenomenon highly similar to what was recently observed in human Vδ1 γδ thymocytes 
(30). We then focused our analyses only on Vδ1pos IELs and the results showed that the sequences of 
NKp46pos and NKp46neg γδ subsets are characterized by highly clonal TRD repertoires and the 
majority of Vδ1 TRD clones uses the Jδ1-joining element (Figure 3C). Notably, the overall TCR 
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repertoire diversity is largely similar between NKp46pos and NKp46neg IELs (Figure 3D). The number 
of shared TRG and TRD clones, calculated between all samples, shows only a few overlapping clones 
within the γδ IEL compartment, mainly Vγ4pos or Vγ9pos (Figure E). Importantly, the most expanded 
TRG and TRD clones do not overlap between NKp46pos and NKp46neg γδ IELs within the same 
individual (Figure 3 A, C and E).   Taken together, the predominant individual clonal TRD and TDG 
repertoires of NKp46pos and NKp46neg IEL subsets and the lack of overlapping clones between 
NKp46pos and NKp46neg γδ IELs suggest that these two IEL subsets emerge from distinct Vδ1 T cell 
progenitors. 
 
NKp46 expression on γδ  IELs is associated with high cytolytic potential and production of IFN-
γ .  
Cytokines such as IL-10, IL-17, IL-22 and transforming growth factor-β (TGF-β) play an 
important role in regulating intestinal immune system homeostasis and are highly enriched in the gut 
mucosa microenvironment (31). In addition, studies have shown that freshly isolated and activated γδ 
IELs express high levels of lymphotactin/XCL1, a chemokine important for CD8pos T cell activity and 
chemotaxis (32). Hence, we compared the transcription levels of these cytokines between circulating 
γδ T cells and fresh FACS-sorted NKp46pos and NKp46neg γδ IELs. Our results showed that both 
NKp46pos and NKp46neg γδ IELs express similarly high mRNA amounts of IL-22 and 
lymphotactin/XCL1 compared to blood γδ T cells, thus highlighting their key roles in intraepithelial 
immune responses and homeostasis. No differences were found for IL-10, IL-17 and TGF-β transcripts 
between NKp46pos and NKp46neg γδ IELs and circulating γδ T cells (Figure 4A). 
 We then analyzed their IFNγ production and cytolytic potential after co-culture with K562 
cells, a tumor target widely employed to test innate cell cytotoxicity (33). NKp46pos and  γδ IELs 
showed a significantly increased production of IFNγ in response to the K562 cells compared to their 
NKp46neg counterparts (Figure 4B). We then observed that the intra-cellular level of Granzyme B 
(GZMB) is constitutively higher in freshly purified NKp46pos γδ IELs compared to their NKp46neg 
counterparts. The incubation with K562 cells further increases the amount of newly synthesized 
intracellularly GZMB both in NKp46pos and NKp46neg γδ IELs. However, the amounts of this cytotoxic 
granule were significantly higher in the first subset compared to the second one (Figure 4C). We then 
measured the degree of CD107a expression as a marker of cytolytic activity. Again, the frequencies of 
CD107apos/NKp46pos γδ IELs were significantly higher compared to that of 
CD107pos/NKp46neg γδ IELs following incubation with K562 (Figure 4D). Additional experiments also 
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confirmed the great cytotoxic potential of NKp46pos γδ IELs in killing human colon adenocarcinoma 
cell targets cell targets (i.e. SKCO1 and Caco2) (Figure 4E).  
To assess the functional relevance of NKp46 in the highly cytotoxic potentials of NKp46pos γδ 
IELs, we tested the ability of these cells to degranulate either in the presence or in the absence of the 
specific anti-NKp46 mAb. The results showed that the masking of NKp46 significantly decreases the 
ability of NKp46pos γδ IELs to kill K562 (Figure 4F), thus demonstrating a direct involvement of this 
aNKR in tuning the cytotoxicity of this specific epithelial γδ T cell subset.  
 
Human γδ  thymocytes resemble the phenotype and functions of NKp46pos Vδ1 IELs following 
activation. 
Maturation of γδ T cells occurs during thymus development that commits γδ T precursors to 
properly differentiate and migrate to peripheral tissues (34). Recently, it has been also reported that the 
acquisition of both cytotoxicity and ability to produce IFN-γ by γδ thymic precursors is not associated 
with the engagement of TCR, but rather requires activation with either IL-2 or IL-15 (35). In order to 
understand whether these two cytokines could induce phenotype and functions similar to those of 
NKp46pos Vδ1 IELs at the level of γδ thymic precursors, we stimulated with both these cytokines γδ 
thymocytes purified from healthy thymus collected from pediatric patients undergoing cardiac surgical 
procedures. The activation with either IL-2 or IL-15 induced a statistically significant increase of 
NKp46, while this was not the case for γδ thymocytes incubated with IL-7 (Figure 5A). Interestingly, 
the activation with IL-2 induced a preferential expansion of the NKp46pos/Vδ1 T cell subset, as we did 
not detect any significant proliferation within the Vδ2 cell compartment (Figure 5 B-C). The expansion 
of Vδ1 thymocytes was mainly associated with an increased de novo expression of NKp46, as we 
observed very few NKp46pos/Vδ1 cells in freshly isolated thymocytes (data not shown). We also found 
that IL-2 activation induces a de novo expression of NKp46 on FACS-sorted Vδ1 thymocytes and not 
on their Vδ2 FACS-sorted counterparts, thus indicating the intrinsic ability of this cytokine to generate 
NKp46pos/Vδ1 T cell from their thymic Vδ1 precursors without the need of additional cellular 
interactions (data not shown).  
Activation with IL-2 induces on γδ thymocytes also a significant de novo expression of NKp44 
and NKp30 receptors, although to a less extent compared to that of NKp46. In contrast, we did not 
detect any induced-expression of NCRs on αβ thymocytes or peripheral γδ T cells following 
incubation with IL-2 (Figure 5D). Similar results were observed with IL15 (data not shown).  
Interestingly, the phenotype of Vδ1 cells expanded from IL-2 activated γδ thymic precursors 
resembles the one of NKp46pos/Vδ1 IELs freshly purified from human intestine. Indeed, the incubation 
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with IL-2 (and with IL-15 as well - data not shown) increased on proliferating Vδ1 thymocytes the 
expression of CD8, CD56 and NKG2D while decreasing the surface levels of CD4. Only NKG2A 
resulted differently expressed on Vδ1pos cells generated from IL-2 activated thymic precursors 
compared to freshly purified intestinal NKp46pos/Vδ1 IELs. Indeed, while this latter subset naturally 
expresses very low levels of this iNKR, the stimulation of thymic precursors with IL-2 induced a 
remarkably high de novo expression of NKG2A on Vδ1pos thymocytes. The IL-2 stimulation also 
triggered a de novo expression on Vδ1pos cells of CCR9, a chemokine-receptor involved in the homing 
of γδ T lymphocytes to the gut mucosa (Figure 6A) (36). This phenomenon is also functionally 
relevant as demonstrated by the chemotactic activity of CCR9 on IL-2-activated NKp46pos/Vδ1 
thymocytes in response to its CCL25 ligand in a dose-dependent manner (Figure 6B). The acquisition 
of NKp46 phenotype on γδ thymocytes following incubation with IL-2 is coupled with significantly 
higher transcription levels of GZMB as well as with an increased degranulation against K562 and 
human tumor epithelial colorectal Caco2 cell lines (Figures 6C-D).  
Taken together, these data indicate that IL-2/IL-15-mediated differentiation of human Vδ1 
thymic precursors result in the acquisition of the gut-like phenotype and potent anti-tumor activity by 
these cells committed to specifically migrate to the gut. 
 
Impact of intestinal microenvironment in the maturation of IL2-activated γδ  thymocytes. 
The preferential enrichment of NKp46pos/Vδ1 T cells in the intestinal epithelium implicates a tight 
interaction with intestinal epithelial cells (IECs). Indeed, the survival and the retention of IELs 
depends on the ligand-activated transcription factor aryl hydrocarbon receptor (AHR) and IL-15 
production by neighboring IECs (37). Hence, we incubated γδ thymocytes with IL-2 in the presence or 
absence of either primary Human Colonic Epithelial cells (HCoEpic) or IL-15. Both these factors had 
a significant synergistic effect in further increasing the expression of NKp46 on IL-2 activated Vδ1 
proliferating thymocytes (Figure 6E). In contrast, we did not observe any change in NKp46 expression 
on IL-2 activated thymocytes co-cultured with IL-10 or IL-12 or IL-22 or thymic stromal 
lymphopoietin (TSLP), the soluble factor produced by IECs to induce T cell maturation at this tissue 
site (38) (data not shown).  
We also analyzed the contribution of TGF-β that is overexpressed in CRC with poor prognosis, 
where this protein plays a key role in the organization of tumor-microenvironment (39). The 
incubation with TGF-β significantly suppressed the IL-2 induced expression of NKp46 on 
proliferating γδ thymocytes. Similar inhibitory results were obtained when IL-2-stimulated 
γδ thymocytes were co-cultured with Caco2 cells (Figure 6E), thus confirming that the intestinal 
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tumor-microenvironment is endowed with escape mechanisms impairing the cytolytic potential of Vδ1 
T cells. 
 
Impact of NKp46pos/Vδ1 IELs on the prognosis and progression of CRC. 
 We then assessed if the frequency of γδ IELs in the “disease-free/healthy” tissue specimens of 
patients affected by CRC correlates with tumor progression. To this end, patients included in the 
analysis were divided into two sub-cohorts either in early (I/II) or late (III/IV) TNM stages of CRC on 
the basis of the widely-used Tumor-Nodes-Metastasis (TNM) staging system. Patients that required 
chemotherapy treatment before surgical resection of CRC were excluded from the analyses to avoid 
any bias on T lymphocytes recurrence. We first observed that the frequencies of total γδ IELs as well 
as of their Vδ1 and Vδ2 subsets did not change in the portions of healthy colon from CRC patients at 
different TNM disease stages (Figures 7 A-B). Interestingly, we found that tumor-free gut specimens 
of CRC patients that progressed toward stages III/IV have a significantly lower frequency of 
NKp46pos/Vδ1 IELs compared to those at earlier I/II stages. This phenomenon appeared to be specific 
for NKp46pos/Vδ1 IELs since no changes in the frequencies of NKp46pos/Vδ2 IELs were found 
between I/II and III/IV CRC stages (Figures 7 C-D).  
We then evaluated the ability of the NKp46pos/Vδ1 subset to infiltrate CRC tumor mass. Since 
this adenocarcinoma originates directly from tumor-transformed IECs and typically disrupt the 
anatomical organization of gut mucosa in epithelial and lamina propria compartments  (Supplemental 
Figure 1B) (21), we measured the frequency of tumor infiltrating lymphocytes (TILs) on the entire 
pathologic specimens without distinguishing between IELs and LPLs. We found that the percentages 
of both total Vδ1 and the NKp46pos/Vδ1 TIL subsets within CRC tumor mass were significantly lower 
compared to the frequencies of IELs in disease-free/healthy gut tissue specimens (Figures 7 E-F).  
Since patients affected by IBD are at higher risk of developing CRC (40), we also evaluated the 
frequency of both Vδ1 cells and NKp46pos/Vδ1 cell subset in patients with ulcerative colitis (UC). 
Again, the percentages of both these intestinal lymphocyte populations in the UC gut specimens were 
significantly lower compared to the frequencies of their IEL counterparts in disease-free/healthy gut 
tissue specimens (Supplemental Figure 7). Taken together, these data suggest that both inflammatory 
and tumor microenvironments are associated with escape mechanisms inhibiting either the migration 
or the in-situ expansion of anti-tumor NKp46pos/Vδ1 IELs.      
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Discussion 
 NKp46 is one of the three NCRs originally identified as germline encoded proteins specifically 
expressed on circulating NK cells and playing key roles in cancer-immune-surveillance (41-44). 
Although NCRs are naturally absent on circulating T cells (17), both NKp46 and NKp44 were 
previously found to be expressed on human intestinal αβ T cells IELs of patients affected by celiac 
disease (45). In this context, a major role was played by IL-15, a pro-inflammatory cytokine 
overexpressed in celiac patients and inducing the expansion of activated NCRpos αβ IELs endowed 
with potent NK-like and TCR-independent anti-tumor effector-functions (46). However, these 
cytotoxic NCRpos αβ IELs were highly restricted in their TCR repertoire, thus likely indicating a 
previous TCR engagement (47). The present study identifies a novel subset of Vδ1 cells constitutively 
expressing high levels of NKp46 and representing the largest γδ IEL subset in healthy human intestine. 
NKp46pos/Vδ1 IELs are not phylogenetically conserved across species (i.e. mice and humans) and are 
not present in blood and other human tissue compartments highly enriched in γδ T cells. Hence, they 
represent a unique population of gut-resident innate-like lymphocytes and a first line of immune-
defense against infections and tumors at mucosal interface. This is, to our knowledge, the biggest 
“natural” (contrasting to induced) (16) NCRpos T cell subset yet identified.  
In this study, we also established a methodology able to induce in vitro an NCRpos phenotype 
on pediatric γδ thymocytes upon stimulation with IL-15 or IL-2, which are the two cytokines playing 
key roles in boosting the γδ T cell cytotoxicity program (35). This is consistent with a previous report 
showing that both IL-15 and IL-2 (but not IL-7) induces NCR expression and cytotoxicity on T cells 
(both αβ and γδ) purified from cord blood (48). Further investigation is needed to understand the 
kinetic and the mechanisms inducing in vivo at the thymus site the expression of NKp46 on Vδ1 
thymocytes as well as their ability to migrate to gut epithelium. 
We previosly reported an inducible expression of NCRs (with NKp30 being the dominant 
family member) also on circulating γδ T cells from adult donors, a phenomenon occurring selectively 
on the Vδ1 T cell subset and requiring both IL-15/IL-2 cell activation and TCR engagement (16). 
NCRpos/Vδ1 T cells generated from peripheral blood hold great potential for adoptive cell therapy, as 
they displayed both in vitro and in vivo (xenograft models) enhanced cytotoxicity against 
hematological tumors and potent anti-viral activities (49, 50). We show here that the constitutive 
expression of NKp46 on freshly purified Vδ1 IELs as well as its induced expression on IL-2/IL-15 
stimulated Vδ1 thymocyte precursors remarkably increase the cytolytic potential of these innate-like 
lymphocytes also against solid (epithelial-derived) tumors. 	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Taken together, these data demonstrate that the presence of NCRs identifies a subset of highly 
cytotoxic γδ T cells either normally resident in the human gut epithelium or expanded in vitro from 
different sources. 
The origin and development of IELs is still the subject of debate. A murine model showed that 
 γδ thymocytes follow maturation waves that sequentially populate different tissues starting with skin 
at early embryonic age and followed by tongue, reproductive tract and intestine at peri- and post-natal 
days (51). In the gut there are multiple cellular sources of IL-15 including IECs (37). On the other 
hand, IL-2 secreted by the neighboring αβ IELs supports the growth of γδ IELs (52). This explains, at 
least in part, the fact that the intestinal epithelium rather than LP is the preferential “natural” 
anatomical location for the newly disclosed NKp46pos/γδ IELs. We show here that IL-2 or IL-15 
stimulation induces in thymocyte precursors the phenotype and functions of NKp46pos/Vδ1 IELs as 
well as the expression of CCR9, thus promoting a specific homing of these cells to the IEL 
compartment (36). In this regard, although IL2/IL15-activated γδ thymocyte precursors share several 
similarities both in phenotype and functions with freshly purified and gut-resident NKp46pos/Vδ1 IELs, 
this latter population lacks the expression of NKG2A in contrast to what we observed in IL-2/IL-15 
stimulated thymocytes. The different surface distribution of this iNKR is likely associated with the fact 
that NKp46pos/Vδ1 T cells generated in vitro from thymic precursors do not directly interact with IECs 
naturally expressing high levels of HLA-E. This non-classical MHC-I complex represents the NKG2A 
natural ligand, whose constitutive high surface level on IECs is a consequence of their chronic stress 
and antigen challenges occurring at the mucosal interface (53). Hence, the binding of HLA-E with 
NKG2A on NKp46pos/Vδ1 intestinal IELs might explain its low detectable expression as a mechanism 
of induced peripheral tolerance under homeostatic conditions and in the presence of alloantigen 
stimulation.  Indeed, NKp46 is involved in the killing of various cancer cells following binding with its 
natural ligands expressed on cancer cells, a phenomenon also associated with cytoskeletal 
rearrangement and higher lytic granules polarization to the immune synapse (41, 43, 44, 54, 55). We 
demonstrate here that the expression of this NCR significantly contributes to the high cytolytic 
potential of NKp46pos/Vδ1 IELs freshly purified from the gut, since its blocking remarkably reduces 
this effector-function. Therefore, while NKp46 expression marks an enhanced cytotoxicity among γδ 
IELs, other receptors such as NKG2A might represent an immune-check point controlling the effector-
functions of NKp46pos/Vδ1 intestinal IELs. Additional studies are required to disclose the mechanisms 
modulating the immune-surveillance thresholds of these newly disclosed subsets of gut resident innate-
like lymphocytes. Taken together, these data indicate that the ontogeny and homeostasis of the 
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NKp46pos/Vδ1 IELs depends both on distinctive features of human Vδ1 thymocytes and gut micro-
environmental factors.  
 The clinical relevance of our newly identified NKp46pos/Vδ1 IELs subset is highlighted by their 
possible impact in the natural history of CRC. Indeed, our results showed that lower frequencies of 
NKp46pos/Vδ1 IELs in healthy intestinal tissues surrounding the tumor mass correlate with a higher 
tumor progression towards metastatic diseases. Interestingly, a recent report showed that the NKp46-
mediated production of IFN-γ by NK cells is able to control tumor progression and decreases 
metastasis in vivo via the induced secretion of fibronectin by malignant cells (56). Furthermore, T cells 
expressing Vδ1 represent the dominant subset among all γδ T cells in CRC patients with an impaired 
IFN-γ production (21). Our data showed significantly lower frequencies of both CRC intra-tumoral 
Vδ1 and NKp46pos/Vδ1 T cells compared to those of their counterparts naturally resident in the healthy 
intraepithelial gut compartment. Incubations of IL-2/IL-15 activated thymocyte precursors with Caco2 
cells or TGFβ (overexpressed in CRC) (39) greatly inhibited the expansion of NKp46pos/Vδ1 Τ cells. 
Both these ex vivo and in vitro data suggest that the local tumor-microenvironment might facilitate 
tumor progression by escaping NKp46pos/Vδ1 IEL cytotoxicity. A recent study reported that the loss of 
butyrophilin-like (BTLN) molecule BTLN8 coincides with permanent loss of the specific gut-resident 
BTLN3/8 reactive Vγ4pos/Vδ1 IEL subset upon inflammatory conditions in celiac disease (57). 
Additional investigations are required to assess if a similar mechanism also contribute to the reduce 
NKp46pos/Vδ1 T cells in human model of cancer like CRC. 
In summary, our identification of a novel gut-resident subset of NKp46pos/Vδ1 IELs endowed 
with enhanced anti-tumor potential paves the ground for developing novel approaches in the field of 
immune-therapy. Indeed, both the possibility of generating from thymic precursors in vitro 
NKp46pos/Vδ1 T cells with high tropism for the gut and the “Delta One T cell” protocol (45), which 
up- regulates NCRs expression on Vδ1 T cells while expanding them to large numbers for adoptive 
transfer, represent promising and alternative ad hoc strategies for CRC treatment. 
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Methods 
Human specimens processing and cell culture 
Healthy intestine tissues were collected from the distal area of the pathological tissue (≥	  10 cm) 
and macroscopically free from any disease. In order to obtain intestinal IELs from healthy intestine 
tissues, gut mucosa was first dissected from the whole tissue and cut in small pieces, washed in Wash 
Buffer (WB) prepared with Hank's Balanced salt solution buffer without Ca2 and Mg2 (HBSS-/-; 
Lonza, Verviers, Belgium) supplemented with 1% penicillin/streptomycin/amphotericin (P/S/A; 
Invitrogen, Paisley, UK), treated with 2 mM of DL-Dithiothreitol (DTT) (Sigma Aldrich, Saint Louis, 
MO, USA) for 15 min at room temperature (RT), washed again and subsequently treated with 2 mM of 
Ethylene-diamine-tetra acetic acid (EDTA; Sigma Aldrich) for 30 min at 37°C/5% CO2. Both cell 
suspensions were filtered through 100 µm cell strainer (Thermo Fisher Scientific, Waltham, MA, 
USA) and cells were collected by centrifugation. The remaining tissue was used to isolate lamina 
propria lymphocytes (LPLs) by enzymatic digestion with 0.75 mg/mL of collagenase II (Sigma 
Aldrich) for 1 hour at 37°C/5% CO2. Obtained cells were filtered through 100 µm cell strainer and 
collected by centrifugation. Finally, both IELs and LPLs were isolated using 30/70% Percoll gradient 
(Sigma Aldrich). Pathological intestine specimens after they were mechanically minced in small pieces 
and washed with WB, followed by enzymatic digestion with 1.5 µg/ml of collagenase IV (Life 
Technologies, Carlsbad, CA), 20µg/ml of hyaluronidase and 50 µg/ml of DNAase (both from Sigma 
Aldrich) for 2 hours at 37°C/5% CO2. Obtained cells were isolated by centrifugation and stained for 
flow cytometry analysis (Supplementary Figures 1A-C).  
Human healthy thymus samples were obtained from children undergoing heart surgery for 
congenital heart diseases according to current clinical practice. Thymic tissue was cleaned from blood 
vessels and fat tissue and cut in small pieces. Thymocytes were recovered through mechanical 
smashing and kept in PBS (Corning; New York, NY, USA) with 1% of P/S, to preserve their viability 
or were frozen in fetal bovine serum (FBS; Lonza) with 10 % of DMSO (Lonza) and stored at -80°C. 
Thawed thymocytes were cultured in 96 well plate round bottom at a concentration of 106 cells /mL in 
X-VIVO™ 15 serum-free hematopoietic cell medium supplemented with: 5% human AB serum, 1% 
P/S/A, 1% ultraglutamine, 1% Na pyruvate and 1% of non-essential amino acid solution (NEAA), all 
purchased from Lonza. Thymocytes cultured in vitro were stimulated with human recombinant IL2 
(200 U/mL, Miltenyi) or with IL-15, IL-7, IL-10, IL-12, IL-22, TGF-β, thymic stromal lymphopoietin 
(TSLP), all used at concentration 10 ng/mL and purchased from Peprotech (Rocky Hill, NJ, USA). 
Human healthy liver tissues were obtained from patients who underwent hepatectomy for 
hepatic metastatic disease from CRC. Tissue specimens were collected from the distal area of the 
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pathological tissue (≥ 4cm) and macroscopically free from any disease. Liver tissue dissociation was 
obtained by enzymatic digestion in gentleMACS™ Dissociator (Miltenyi) with 2 mg/mL of 
collagenase D (Roche Diagnostic; Indianapolis, IN, USA) for 45 minutes at 37°C/5% CO2. Cells then 
were filtered through 100 µm cell strainers, washed in HBSS-/- and lymphocytes were separated using 
30/70 % Percoll gradient. 
Human healthy skin was obtained from patients who undergo abdominoplasty or mastoplasty 
surgical procedures. Skin specimens were cut in small pieces and lymphocytes were recuperated by 
enzymatic digestion with 1.25 U/mL of Dispase II (Roche Diagnostic) initially for 16 hours at 4°C 
followed by 30 minutes at 37°C. Solution containing epidermal lymphocytes was filtered through 
100 µm cell strainers, and cells were washed in HBSS-/- with5mM EDTA. Remaining tissue was 
further digested with 1 mg/mL collagenase D and 1.25 U/mL of Dispase II 30 minutes at 37°C in order 
to recover dermis lymphocytes. Cells then were filtered through 100 µm cell strainers, washed in 
HBSS-/- with 5 mM EDTA and lymphocytes were separated using 30/70 % Percoll gradient. 
Human healthy/non-reactive lymph nodes obtained from patients with Whartin’s tumor or 
hyperplasia of salivary glands. Lymph nodes were mechanically smashed in HBSS-/- through 100 µm 
cell strainers and cells were collected by centrifugation.  
Human peripheral blood mononuclear cells (PBMC) were isolated from buffy coats of healthy 
volunteers (HRH, Rozzano, Italy) using Lympholyte® Cell Separation density gradient solution 
(Cederlane laboratories, Burlington, Canada) according to the manufacturer’s instruction. 
Primary human colonic epithelial cells (HCoEpic, Cat. No.2950; ScienCell Research 
Laboratories; Carlsbad, CA, USA) were cultured on poly-L-lysine (Sigma Aldrich) following 
manufacturer’s instructions in the specific colonic epithelial cell medium (CoEpiCM, Cat. No.2951) 
supplemented with colonic epithelial cell growth supplement (CoEpiCGS, Cat. No.2952) and 1% 
P/S/A. 
Human leukemia cell line K562 (Cat. No.CCL-243; ATCC; Manassas, VA, USA ) and colon 
cancer adenocarcinoma Caco2 (Cat. No.HTB37; ATCC; Manassas, VA, USA), mycoplasma free, 
were cultured in Iscove's Modified Dulbecco's medium (IMDM; Lonza) or Dulbecco's Modified 
Eagle's medium (DMEM; Lonza) respectively, both supplemented with 10% FBS, 1% P/S/A, 1% 
ultraglutamine. Additional supplements of 1% Na pyruvate and 1% NEAA were added to the Caco2 
cell culture medium.  
Human SKCO-1 colorectal adenocarcinoma cell line from a metastatic site (ATCC; Cat. 
No.HTB-39), mycoplasma free, was cultured in Eagle's Minimum Essential medium (EMEM; ATCC) 
supplemented with 10% FBS and 1% P/S/A. 
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Mice 
Balb-c and C57BL/6  mice were purchased by Charles River (Wilmington, MA, USA) and 
maintained under pathogen-free conditions.  
Small intestine, colon and spleen specimens were dissected and collected at 4°C in RPMI 1640 
(Lonza) medium supplemented with: 10% FBS, 1% P/S/A and 1% ultraglutamine. Cleaned from 
peyers patches, small intestine and colon tissue were cut in small pieces and treated twice with 1 mM 
DTT solution (Sigma Aldrich) for 20 min at 37C°/5% CO2. Cells were then filtered with 70 µm cell 
strainer and washed with WB. Total lymphocytes were obtained using 30/70% of Percoll gradient 
(Sigma Aldrich). Spleen was mechanically smashed in a 100 µm cell strainer (Thermo Fisher 
Scientific), washed with the Wash buffer and filtered in 50 µm cell strainer to obtain single-cell 
suspension of splenocytes.  
 
Flow cytometry 
For multiparametric flow cytometry analysis a standard staining protocol for extracellular 
markers was used. Briefly, cells were first stained for live/dead discrimination by using Zombie 
Aqua™ fixable viability kit (BioLegend; San Diego, CA, USA) or 7-Aminoactinomycin D (7-ADD; 
BD Pharmigen). Subsequently cells were washed with FACS WB (HBSS-/- with 2% of FBS), 
incubated with antibody (Ab) mix for 20 min in the dark at RT, washed again in and fixed in 1% 
paraformaldehyde (PFA; Santa Cruz Biotechnology, Dallas, TX, USA). Samples were acquired using 
LSRFortessa™ cell analyzer system or FACS Canto II (both from BD Bioscience; San Jose, CA, 
USA). FACS Aria III cell sorter (BD Bioscieces) was used for the specific cell subsets separation and 
in vitro assays, for sorting experiments cells were stained with 7-ADD to discriminate dead cells and 
the appropriate mix of Abs for 20 min in the dark at RT. The optimal concentration of all Abs used in 
the study was defined performing a titration experiment. According to the guidelines for an accurate 
multicolor flow cytometry analysis fluorescence minus one (FMO) controls were used for flow 
cytometry analysis. 
For phenotypic analysis, the following specific anti-human monoclonal antibodies (mAbs; Cat. 
No/clone) were used. From BioLegend: CD3 (317324/SK7; BV650 and 300306/HIT3a; FITC), CD4 
(300534/RPAT4; BV570 or 317438; BV605), CD16 (302025/3G8; AF700), CD69 (310938/FN50; 
BV605), CD103 (350206/BERACT9; PE), γδ TCR (331208/B1; FITC), NKG2D (320812/ID11; 
PECy7), NKp46 (331914/9E2; BV421), CCR9 (358906/L053E8; PerCPCy5.5); from BD Biosciences: 
CD8α (563823/RPAT8; BV780), CD45 (560566/H130; AF700 and 557833/2D1; APCCy7), CD56 
(562289/B159; PE-CF594), CD69 (555533/FN50; APC); NKp30 (563383/P3015; BV711); from 
Miltenyi Biotec (Bergish Gladbach, Germany): CD45 (130096609/5B1; APCVio770), KIRs 
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(130103937/REA293; APCVio770 and 130095285/DX27; PerCPCy5.5), Vδ1 (130120440/REA173; 
PE and 130100542; PEVio770), NKG2A (130098812/REA111; APC), from eBioscience: CD8β 
(25527342/5IDI8BEE; PECy7), from Beckman Coulter (Brea, CA,USA) Vδ2 (IM1464/IMMU-389; 
FITC) and NKp44 (PNA66903/Z231; PECy5); from R&D system (Minneapolis, MN, USA) NKG2C 
(FAB138C/134591; PerCP). 
Mouse γδ T lymphocytes were stained with live/dead discriminating marker 7-ADD and with 
the specific anti-mouse mix of mAbs: CD3 (555274/17A2; FITC), NKp46 (561169/29A1.4; AF700) 
(both from BD Pharmigen) and γδ TCR (17571182/eBioGL3; APC) (eBioscience). 
Cell cytotoxic activity was assessed by CD107a flow cytometry-based assay. Freshly isolated 
effector IELs or thymocytes were plated in 96 well plate at a concentration 106 cells/mL in the 
presence or not of target cells K562 or Caco2 at a ratio of E:T=1:1 in X-VIVO™ 15 complete medium 
and 8 µg/mL of PE-conjugated anti-CD107a Ab (555801/H4A3; BD Biosciences). After 4 hours of 
incubation at 37°C/5% CO2 cells were collected, washed in HBSS-/- and stained for extracellular 
markers as described above. PBMC obtained from healthy donors pre-stimulated 1 hour with PMA 
(0.5 µg/mL) and Ionomycin (0.1 µg/mL) (both from Sigma Aldrich) were used as the control of the 
degranulation assay. For masking experiments, the specific anti-hNKp46 IgM blocking mAb (KL247) 
was kindly provided by Prof. Silvia Parolini, University of Brescia, Brescia, Italy (58).  
Intracellular IFN-γ, TNF-α and GZMB accumulation was measured by flow cytometry. Freshly 
isolated IELs were plated in 96 well plate round bottom at a concentration of 106 cells /mL with or 
without target cells K562 at a ratio of E:T = 1:1 and in the presence of 1µg/mL of Golgi Plug, protein 
transport inhibitor (BD Biosciences). As a protein transport inhibitor (containing Brefeldin A), Golgi 
Plug, was able to trap the amounts of newly synthesize (i.e. increased intracellulare levels) Granzyme 
B and IFN-γ at intracellular site in response to activation stimuli. After 4 hours at 37°C/5% CO2 IELs 
were collected, washed with HBSS-/- and extracellular staining as described above was performed. 
Subsequently intracellular staining was done using Cytofix/CytopermTM and Perm/WashTM kits (BD 
Biosciences) according to the manufacturer’s instructions and using specific anti-human Abs (BD 
Biosciences) for for TNF-α (559321/Mab11; PE), IFN-γ (564039/B27; BV711) and GZMB 
(560212/GB11; AF647).  
For chemotaxis experiments, viable CD45pos/CD3pos/γδ TCRpos/NKp46pos IL-2 activated human 
thymocytes were sorted and plated in X-VIVO™ 15 complete medium in the basket of the trans-well 
with 8.0 µm large pore (Corning). Human recombinant CCL25 (BioLegend) was added to the bottom 
of the trans-wells at different concentration 0, 25 and 50 ng/mL and left 6 hours at 37°C/5% CO2. 
After this time cells were collected and counted by LSRFortessa™ flow cytometry for quantification. 
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High-throughput analysis of TRG and TRD repertoires  
CDR3 regions of either the γ-chain (TRG) or δ-chain (TRD) were amplified from flow 
cytometry-sorted NKp46pos and NKp46neg Vδ1 IELs via a previously described mRNA-based 
multiplex PCR amplification method (59). PCR amplicons were indexed with the Illumina Nextera 
Index Kit, purified with Agencourt AMPure beads, equally pooled with 96-samples and sequenced at 
the Illumina MiSeq platform (paired-end, 500 cycles, high-output) as recommended by Illumina 
guidelines, while 20% PhIX was used as a spike-in control. The obtained fastq files of read1 were 
annotated with MiXCR software (60) using default parameters and further analyzed with the R 
package TcR (PMID: 26017500) and VDJtools (61, 62). For TRD repertoires only Vδ1pos sequences 
were processed after MiXCR annotation. Treemaps were generated with the R package treemap. The 
deposited bio-project number is PRJNA558198 
 
qPCR 
Total RNA of sorted γδ T NKp46pos and NKp46neg IELs/thymocytes was extracted using 
RNasy micro-plus columns with RNase-free DNase treatment and RNA carrier (Qiagen Valencia, CA, 
USA) following the manufacturer’s instructions. Extracted RNA was used to generate cDNA 
templates for qPCR using High-Capacity cDNA Reverse Transcription Kit with random primers and 
RNase inhibitor (Applied Biosystem, Foster City, CA, USA). 100 ng of total cDNA were pre-
amplified for the specific gene expression using TaqMan®mRNA gene assays and TaqMan® PreAmp 
Master Mix (both from Applied Biosystem). QPCR reactions were performed by Real Time AB7900 
(Applied Biosystem) with TaqMan® Universal PCR Master Mix and the specific TaqMan®mRNA 
gene assays (Applied Biosystem): NCR1 (HS00183683), IL10 (HS00961622), IL17A (HS00174383), 
TGFβ (HS00998133), IL22 (HS01574154), IFNγ (HS00989291), GZMB (HS01554355), XCL1 
(HS00751481) and housekeeping S18 (HS01026310) and GAPDH (HS02758991). PCR-based 
detection of mycoplasmal DNA was performed using BioMixTM (Bioline, London, UK).and GPO-1 
(5’-ACTCCTACGGGAGGCAGCAGT-3’) and MGSO  
(5’ -TGCACCATCTGTCACTCTGTTAACCTC-3’) primers from IDT (Coralville, IA, USA). 
Immunohistochemistry and Immunofluorescence 
Formalin-fixed paraffin-embedded liver specimens, previously sectioned with a microtome 
HM310 Microm (GMI, MN, USA) at 2-4 µm thickness and mounted onto charged glass slides 
Superfrost+ (Thermo Fisher Scientific), were stained with H&E using a standard protocol. Briefly, 
after two changes of xylenes, rehydration in an ethanol/water gradient (100%, 90%, 70%), followed 
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by washing in water, slides were stained with in Mayer’s Hematoxylin solution (Dako, CA; USA) for 
18 min, differentiated under running tap water for 10 min, then stained with 1% aqueous solution of Y 
Eosin (Dako) for 8 min, followed by three washes with 100% ethanol, and three washed with xylenes. 
Lastly H&E stained slides were mounted with Eukitt (Sigma Aldrich) and dried prior to imaging by 
Microscope BX51 (Olympus, Tokyo, Japan). 
Freshly isolated tissues were fixed with 4% paraformaldehyde for 2 hours, washed and 
incubated overnight in 30% sucrose. Tissues were then embedded in OCT, frozen in a bath of 
isopentane cooled on dry ice, and cut in 8 µm-­‐thick sections.	  Human NKp46 staining was then 
performed using polyclonal goat anti-­‐human NKp46 (Cat. No.AF1850; R&D Systems; used 20 
µg/mL), polyclonal rabbit anti-­‐human CD3 (No.A0452; Dako, CA; USA; diluted 1:50) and mouse 
monoclonal anti-­‐human TCR-PAN γδ (COIM1349/IMMU510) (10 µg/mL) then followed by the 
following secondary antibodies raised in donkey (Invitrogen): anti-­‐rabbit Alexa488, anti-­‐mouse 
Alexa594, and anti-­‐goat Alexa647, all used at concentration of 1:1000. Nuclei were counterstained 
with DAPI (Invitrogen) at concentration of 1:50000. After staining, slides were dried, mounted with 
Prolong Gold (Invitrogen) and examined under Zeiss LSM 510 confocal microscope (Zeiss, Germany). 
Image processing was performed with Zeiss LSM and Adobe Photoshop software 
 
Statistics 
Statistical analyses were performed using GraphPad Prism version 7. For the comparison of 
two matched groups of samples (specified in the legend) Wilcoxon t test was applied or non-paired 
Mann-Whitney t test was applied. Experiments with more than two groups were analyzed by Kruskal-
Wallis with Dunn's post-hoc multiple comparisons test. When specified, Pearson’s data correlation and 
R-Squared analyses were used. The data are depicted as vertical bars corresponding to mean value 
±estimated standard error (SEM) with scatter dots or as box and whisker plots with the median value 
displayed inside the box and the maximum and minimum values displayed with whiskers. Some 
graphs are represented as scattered plots of paired observations. P values > 0.05 were considered not 
statistically significant (ns). Statistically significant P values were represented with GraphPad (GP) 
style and summarized with following number of asterisks (*): *P≤0.05; **P≤0.01; ***P≤0.001; 
****P≤0.0001. Flow cytometry data were analyzed by FlowJo software version 9.4 and 9.6 (FlowJo 
LLC; Ashland, OR, USA). Flow cytometry data analysis based on t-SNE algorithm were performed 
using FlowJo 9.6 software. 
 
 
	  
22	  |	  P a g e 	   	   M i k u l a k  J .  e t  a l . 	  
	  
Study approval 
Patient recruitment and samples collection have been performed according to the Declaration of 
Helsinki. The collection of human samples for research purposes was ethically approved by the 
Institutional review Board (IRB) of Humanitas Research Hospital (HRH) for blood and gut specimens 
either free of diseases of affected by CRC or Inflammatory Bowel Diseases (IBDs) of patients 
undergoing surgical gut resection and for healthy skin of patients undergoing plastic surgical 
procedures (approval 2012/1021), for healthy lymph nodes of patients undergoing the removal of 
benign head-neck tumors (approval 2010/700), for healthy liver specimens of patients undergoing 
resection of CRC metastasis (approval 168/18). We also received IRB approval from the University 
Hospital of Palermo (UNIPA) for the collection of gut specimens affected by CRC of patients 
undergoing surgical gut resection (approval 13/2013) and from the IRB of TIGET/San Raffaele 
Institute for specimens of healthy thymus from pediatric patients undergoing cardiac surgery (approval 
TIGET07, TCTO-044). All participants or parents with the custody of the child undergoing cardiac 
surgery were informed about the aims of this research program and signed a detailed informed consent. 
  Animal experiments adhered to the requirements of the European Commission Directive 
86/609/EEC and to the Italian legislation (Decreto Legislativo 116; 27 January 1992). Experiments 
were approved by the Animal Care and Use Committee from Italian Ministry of Health (approval 
158/2011).   
  
23	  |	  P a g e 	   	   M i k u l a k  J .  e t  a l . 	  
	  
Author Contributions 
J.M., F.O., E.B., A.R., B.S.S. and D.M. designed and performed experiments; A.V., M.B., I.B., 
E.L.P., S.M., F.D., S.V., S.D., S.D.B., M.M.C., M.S., G. Cu., G. Co., E.M., M.K. and A.S. provided 
biological specimens, reagents and experimental protocols; F.S.C. provided assistance with flow 
cytometry and cell sorting; P.S. and M.R. provided pathologic examination of tissue specimens; I.P., 
S.R. and B.L. performed TCR repertoire sequencing and analysis; J.M., F.O. and D.M. designed the 
study, analyzed data and wrote the manuscript; D.M. directed the study.    
 
Acknowledgments	  
The authors thank the patients for their generosity and participation in this study and the nurses of the 
Colon and Rectal Surgery Unit (Humanitas Clinical and Research Center). We thank Matteo Cimino, 
Matteo Donadon and Guido Torzilli from Humanitas Clinical and Research Center and Humanitas 
University for providing specimens of human healthy liver, Genni Enza Marcovecchio from San 
Raffaele Scientific Institute for providing specimens of healthy human thymus. We thank Kelly 
Hudspeth, Elena Pontarini and Manuela Lo Porto from Humanitas Clinical and Research Center for 
their help in the implementation of experimental protocols and Stefano Mantero from Consiglio 
Nazionale delle Ricerche for his support in immunochemistry. We thank also Prof. Silvia Parolini from 
University of Brescia, Brescia, Italy for anti-NKp46 blocking mAb. 
 
This work was supported by Associazione Italiana per la Ricerca sul Cancro (IG 14687 to 
D.M), by the Italian Ministry of Health (Bando Giovani Ricercatori GR2011023477381 to K.H. and 
GR-2013-02356522 to A.R.) and intramural research and clinical funding programs of Humanitas 
Research Hospital (to D.M.) and by Fondazione Telethon (SR-Tiget F3 core grant to MB) and 
National Program of CNR Aging Project (to A.V). 
	  
Competing Interests 
B.S.-S. is a co-founder and shareholder of Lymphact – Lymphocyte Activation Technologies 
S.A. The remaining authors declared no competing financial interests. 
 
24	  |	  P a g e 	   	   M i k u l a k  J .  e t  a l . 	  
	  
References	  
1.	   Mowat,	  A.M.,	  and	  Agace,	  W.W.	  2014.	  Regional	  specialization	  within	  the	  intestinal	  immune	  system.	  Nat	  
Rev	  Immunol	  14:667-­‐685.	  
2.	   Gopalakrishnan,	  V.,	  Spencer,	  C.N.,	  Nezi,	  L.,	  Reuben,	  A.,	  Andrews,	  M.C.,	  Karpinets,	  T.V.,	  Prieto,	  P.A.,	  
Vicente,	  D.,	  Hoffman,	  K.,	  Wei,	  S.C.,	  et	  al.	  2018.	  Gut	  microbiome	  modulates	  response	  to	  anti-­‐PD-­‐1	  
immunotherapy	  in	  melanoma	  patients.	  Science	  359:97-­‐103.	  
3.	   Deusch,	  K.,	  Luling,	  F.,	  Reich,	  K.,	  Classen,	  M.,	  Wagner,	  H.,	  and	  Pfeffer,	  K.	  1991.	  A	  major	  fraction	  of	  
human	  intraepithelial	  lymphocytes	  simultaneously	  expresses	  the	  gamma/delta	  T	  cell	  receptor,	  the	  CD8	  
accessory	  molecule	  and	  preferentially	  uses	  the	  V	  delta	  1	  gene	  segment.	  Eur	  J	  Immunol	  21:1053-­‐1059.	  
4.	   Chien,	  Y.H.,	  Meyer,	  C.,	  and	  Bonneville,	  M.	  2014.	  gammadelta	  T	  cells:	  first	  line	  of	  defense	  and	  beyond.	  
Annu	  Rev	  Immunol	  32:121-­‐155.	  
5.	   Nielsen,	  M.M.,	  Witherden,	  D.A.,	  and	  Havran,	  W.L.	  2017.	  gammadelta	  T	  cells	  in	  homeostasis	  and	  host	  
defence	  of	  epithelial	  barrier	  tissues.	  Nat	  Rev	  Immunol	  17:733-­‐745.	  
6.	   Roberts,	  S.J.,	  Smith,	  A.L.,	  West,	  A.B.,	  Wen,	  L.,	  Findly,	  R.C.,	  Owen,	  M.J.,	  and	  Hayday,	  A.C.	  1996.	  T-­‐cell	  
alpha	  beta	  +	  and	  gamma	  delta	  +	  deficient	  mice	  display	  abnormal	  but	  distinct	  phenotypes	  toward	  a	  
natural,	  widespread	  infection	  of	  the	  intestinal	  epithelium.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A	  93:11774-­‐11779.	  
7.	   Fujihashi,	  K.,	  Dohi,	  T.,	  Kweon,	  M.N.,	  McGhee,	  J.R.,	  Koga,	  T.,	  Cooper,	  M.D.,	  Tonegawa,	  S.,	  and	  Kiyono,	  H.	  
1999.	  gammadelta	  T	  cells	  regulate	  mucosally	  induced	  tolerance	  in	  a	  dose-­‐dependent	  fashion.	  Int	  
Immunol	  11:1907-­‐1916.	  
8.	   Vantourout,	  P.,	  and	  Hayday,	  A.	  2013.	  Six-­‐of-­‐the-­‐best:	  unique	  contributions	  of	  gamma	  delta	  T	  cells	  to	  
immunology.	  Nature	  Reviews	  Immunology	  13:88-­‐100.	  
9.	   Bottino,	  C.,	  Tambussi,	  G.,	  Ferrini,	  S.,	  Ciccone,	  E.,	  Varese,	  P.,	  Mingari,	  M.C.,	  Moretta,	  L.,	  and	  Moretta,	  A.	  
1988.	  Two	  subsets	  of	  human	  T	  lymphocytes	  expressing	  gamma/delta	  antigen	  receptor	  are	  identifiable	  
by	  monoclonal	  antibodies	  directed	  to	  two	  distinct	  molecular	  forms	  of	  the	  receptor.	  J	  Exp	  Med	  168:491-­‐
505.	  
10.	   Scotet,	  E.,	  Martinez,	  L.O.,	  Grant,	  E.,	  Barbaras,	  R.,	  Jeno,	  P.,	  Guiraud,	  M.,	  Monsarrat,	  B.,	  Saulquin,	  X.,	  
Maillet,	  S.,	  Esteve,	  J.P.,	  et	  al.	  2005.	  Tumor	  recognition	  following	  V	  gamma	  9V	  delta	  2	  T	  cell	  receptor	  
interactions	  with	  a	  surface	  F1-­‐ATPase-­‐related	  structure	  and	  apolipoprotein	  A-­‐I.	  Immunity	  22:71-­‐80.	  
11.	   Tanaka,	  Y.,	  Morita,	  C.T.,	  Nieves,	  E.,	  Brenner,	  M.B.,	  and	  Bloom,	  B.R.	  1995.	  Natural	  and	  synthetic	  non-­‐
peptide	  antigens	  recognized	  by	  human	  gamma	  delta	  T	  cells.	  Nature	  375:155-­‐158.	  
12.	   Gober,	  H.J.,	  Kistowska,	  M.,	  Angman,	  L.,	  Jeno,	  P.,	  Mori,	  L.,	  and	  De	  Libero,	  G.	  2003.	  Human	  T	  cell	  receptor	  
gamma	  delta	  cells	  recognize	  endogenous	  mevalonate	  metabolites	  in	  tumor	  cells.	  Journal	  of	  
Experimental	  Medicine	  197:163-­‐168.	  
13.	   Zou,	  C.,	  Zhao,	  P.,	  Xiao,	  Z.,	  Han,	  X.,	  Fu,	  F.,	  and	  Fu,	  L.	  2017.	  gammadelta	  T	  cells	  in	  cancer	  immunotherapy.	  
Oncotarget	  8:8900-­‐8909.	  
14.	   Silva-­‐Santos,	  B.,	  Serre,	  K.,	  and	  Norell,	  H.	  2015.	  gammadelta	  T	  cells	  in	  cancer.	  Nat	  Rev	  Immunol	  15:683-­‐
691.	  
15.	   Correia,	  D.V.,	  Lopes,	  A.,	  and	  Silva-­‐Santos,	  B.	  2013.	  Tumor	  cell	  recognition	  by	  gammadelta	  T	  
lymphocytes:	  T-­‐cell	  receptor	  vs.	  NK-­‐cell	  receptors.	  Oncoimmunology	  2:e22892.	  
16.	   Correia,	  D.V.,	  Fogli,	  M.,	  Hudspeth,	  K.,	  da	  Silva,	  M.G.,	  Mavilio,	  D.,	  and	  Silva-­‐Santos,	  B.	  2011.	  
Differentiation	  of	  human	  peripheral	  blood	  Vdelta1+	  T	  cells	  expressing	  the	  natural	  cytotoxicity	  receptor	  
NKp30	  for	  recognition	  of	  lymphoid	  leukemia	  cells.	  Blood	  118:992-­‐1001.	  
17.	   Hudspeth,	  K.,	  Silva-­‐Santos,	  B.,	  and	  Mavilio,	  D.	  2013.	  Natural	  cytotoxicity	  receptors:	  broader	  expression	  
patterns	  and	  functions	  in	  innate	  and	  adaptive	  immune	  cells.	  Frontiers	  in	  Immunology	  4.	  
18.	   Wu,	  D.,	  Wu,	  P.,	  Qiu,	  F.M.,	  Wei,	  Q.C.,	  and	  Huang,	  J.	  2017.	  Human	  gamma	  delta	  T-­‐cell	  subsets	  and	  their	  
involvement	  in	  tumor	  immunity.	  Cellular	  &	  Molecular	  Immunology	  14:245-­‐253.	  
19.	   Pang,	  D.J.,	  Neves,	  J.F.,	  Sumaria,	  N.,	  and	  Pennington,	  D.J.	  2012.	  Understanding	  the	  complexity	  of	  
gammadelta	  T-­‐cell	  subsets	  in	  mouse	  and	  human.	  Immunology	  136:283-­‐290.	  
20.	   Gentles,	  A.J.,	  Newman,	  A.M.,	  Liu,	  C.L.,	  Bratman,	  S.V.,	  Feng,	  W.,	  Kim,	  D.,	  Nair,	  V.S.,	  Xu,	  Y.,	  Khuong,	  A.,	  
Hoang,	  C.D.,	  et	  al.	  2015.	  The	  prognostic	  landscape	  of	  genes	  and	  infiltrating	  immune	  cells	  across	  human	  
cancers.	  Nat	  Med	  21:938-­‐945.	  
25	  |	  P a g e 	   	   M i k u l a k  J .  e t  a l . 	  
	  
21.	   Meraviglia,	  S.,	  Lo	  Presti,	  E.,	  Tosolini,	  M.,	  La	  Mendola,	  C.,	  Orlando,	  V.,	  Todaro,	  M.,	  Catalano,	  V.,	  Stassi,	  
G.,	  Cicero,	  G.,	  Vieni,	  S.,	  et	  al.	  2017.	  Distinctive	  features	  of	  tumor-­‐infiltrating	  gammadelta	  T	  lymphocytes	  
in	  human	  colorectal	  cancer.	  Oncoimmunology	  6:e1347742.	  
22.	   Gibbons,	  D.L.,	  and	  Spencer,	  J.	  2011.	  Mouse	  and	  human	  intestinal	  immunity:	  same	  ballpark,	  different	  
players;	  different	  rules,	  same	  score.	  Mucosal	  Immunol	  4:148-­‐157.	  
23.	   Sathaliyawala,	  T.,	  Kubota,	  M.,	  Yudanin,	  N.,	  Turner,	  D.,	  Camp,	  P.,	  Thome,	  J.J.,	  Bickham,	  K.L.,	  Lerner,	  H.,	  
Goldstein,	  M.,	  Sykes,	  M.,	  et	  al.	  2013.	  Distribution	  and	  compartmentalization	  of	  human	  circulating	  and	  
tissue-­‐resident	  memory	  T	  cell	  subsets.	  Immunity	  38:187-­‐197.	  
24.	   Cepek,	  K.L.,	  Shaw,	  S.K.,	  Parker,	  C.M.,	  Russell,	  G.J.,	  Morrow,	  J.S.,	  Rimm,	  D.L.,	  and	  Brenner,	  M.B.	  1994.	  
Adhesion	  between	  epithelial	  cells	  and	  T	  lymphocytes	  mediated	  by	  E-­‐cadherin	  and	  the	  alpha	  E	  beta	  7	  
integrin.	  Nature	  372:190-­‐193.	  
25.	   Hayday,	  A.,	  Theodoridis,	  E.,	  Ramsburg,	  E.,	  and	  Shires,	  J.	  2001.	  Intraepithelial	  lymphocytes:	  exploring	  
the	  Third	  Way	  in	  immunology.	  Nat	  Immunol	  2:997-­‐1003.	  
26.	   Kadivar,	  M.,	  Petersson,	  J.,	  Svensson,	  L.,	  and	  Marsal,	  J.	  2016.	  CD8	  alpha	  beta(+)	  gamma	  delta	  T	  Cells:	  A	  
Novel	  T	  Cell	  Subset	  with	  a	  Potential	  Role	  in	  Inflammatory	  Bowel	  Disease.	  Journal	  of	  Immunology	  
197:4584-­‐4592.	  
27.	   Hunter,	  S.,	  Willcox,	  C.R.,	  Davey,	  M.S.,	  Kasatskaya,	  S.A.,	  Jeffery,	  H.C.,	  Chudakov,	  D.M.,	  Oo,	  Y.H.,	  and	  
Willcox,	  B.E.	  2018.	  Human	  liver	  infiltrating	  gammadelta	  T	  cells	  are	  composed	  of	  clonally	  expanded	  
circulating	  and	  tissue-­‐resident	  populations.	  J	  Hepatol	  69:654-­‐665.	  
28.	   Hudspeth,	  K.,	  Donadon,	  M.,	  Cimino,	  M.,	  Pontarini,	  E.,	  Tentorio,	  P.,	  Preti,	  M.,	  Hong,	  M.,	  Bertoletti,	  A.,	  
Bicciato,	  S.,	  Invernizzi,	  P.,	  et	  al.	  2016.	  Human	  liver-­‐resident	  CD56(bright)/CD16(neg)	  NK	  cells	  are	  
retained	  within	  hepatic	  sinusoids	  via	  the	  engagement	  of	  CCR5	  and	  CXCR6	  pathways.	  J	  Autoimmun	  
66:40-­‐50.	  
29.	   Tomasello,	  E.,	  Yessaad,	  N.,	  Gregoire,	  E.,	  Hudspeth,	  K.,	  Luci,	  C.,	  Mavilio,	  D.,	  Hardwigsen,	  J.,	  and	  Vivier,	  E.	  
2012.	  Mapping	  of	  NKp46(+)	  Cells	  in	  Healthy	  Human	  Lymphoid	  and	  Non-­‐Lymphoid	  Tissues.	  Front	  
Immunol	  3:344.	  
30.	   Di	  Lorenzo,	  B.,	  Ravens,	  S.,	  and	  Silva-­‐Santos,	  B.	  2019.	  High-­‐throughput	  analysis	  of	  the	  human	  thymic	  
Vdelta1(+)	  T	  cell	  receptor	  repertoire.	  Sci	  Data	  6:115.	  
31.	   Bamias,	  G.,	  Arseneau,	  K.O.,	  and	  Cominelli,	  F.	  2014.	  Cytokines	  and	  mucosal	  immunity.	  Curr	  Opin	  
Gastroenterol	  30:547-­‐552.	  
32.	   Boismenu,	  R.,	  Feng,	  L.,	  Xia,	  Y.Y.,	  Chang,	  J.C.,	  and	  Havran,	  W.L.	  1996.	  Chemokine	  expression	  by	  
intraepithelial	  gamma	  delta	  T	  cells.	  Implications	  for	  the	  recruitment	  of	  inflammatory	  cells	  to	  damaged	  
epithelia.	  J	  Immunol	  157:985-­‐992.	  
33.	   Gomes,	  A.Q.,	  Correia,	  D.V.,	  Grosso,	  A.R.,	  Lanca,	  T.,	  Ferreira,	  C.,	  Lacerda,	  J.F.,	  Barata,	  J.T.,	  da	  Silva,	  M.G.,	  
and	  Silva-­‐Santos,	  B.	  2010.	  Identification	  of	  a	  panel	  of	  ten	  cell	  surface	  protein	  antigens	  associated	  with	  
immunotargeting	  of	  leukemias	  and	  lymphomas	  by	  peripheral	  blood	  gamma	  delta	  T	  cells.	  
Haematologica-­‐the	  Hematology	  Journal	  95:1397-­‐1404.	  
34.	   Van	  de	  Walle,	  I.,	  Waegemans,	  E.,	  De	  Medts,	  J.,	  De	  Smet,	  G.,	  De	  Smedt,	  M.,	  Snauwaert,	  S.,	  
Vandekerckhove,	  B.,	  Kerre,	  T.,	  Leclercq,	  G.,	  Plum,	  J.,	  et	  al.	  2013.	  Specific	  Notch	  receptor-­‐ligand	  
interactions	  control	  human	  TCR-­‐alpha	  beta/gamma	  delta	  development	  by	  inducing	  differential	  Notch	  
signal	  strength.	  Journal	  of	  Experimental	  Medicine	  210:683-­‐697.	  
35.	   Ribot,	  J.C.,	  Ribeiro,	  S.T.,	  Correia,	  D.V.,	  Sousa,	  A.E.,	  and	  Silva-­‐Santos,	  B.	  2014.	  Human	  gammadelta	  
thymocytes	  are	  functionally	  immature	  and	  differentiate	  into	  cytotoxic	  type	  1	  effector	  T	  cells	  upon	  IL-­‐
2/IL-­‐15	  signaling.	  J	  Immunol	  192:2237-­‐2243.	  
36.	   Kabelitz,	  D.,	  and	  Wesch,	  D.	  2003.	  Features	  and	  functions	  of	  gamma	  delta	  T	  lymphocytes:	  Focus	  on	  
chemokines	  and	  their	  receptors.	  Critical	  Reviews	  in	  Immunology	  23:339-­‐370.	  
37.	   Qiu,	  Y.,	  Wang,	  W.,	  Xiao,	  W.,	  and	  Yang,	  H.	  2015.	  Role	  of	  the	  intestinal	  cytokine	  microenvironment	  in	  
shaping	  the	  intraepithelial	  lymphocyte	  repertoire.	  J	  Leukoc	  Biol	  97:849-­‐857.	  
38.	   Ziegler,	  S.F.,	  and	  Liu,	  Y.J.	  2006.	  Thymic	  stromal	  lymphopoietin	  in	  normal	  and	  pathogenic	  T	  cell	  
development	  and	  function.	  Nature	  Immunology	  7:709-­‐714.	  
39.	   Tauriello,	  D.V.F.,	  and	  Batlle,	  E.	  2016.	  Targeting	  the	  Microenvironment	  in	  Advanced	  Colorectal	  Cancer.	  
Trends	  Cancer	  2:495-­‐504.	  
26	  |	  P a g e 	   	   M i k u l a k  J .  e t  a l . 	  
	  
40.	   Janakiram,	  N.B.,	  and	  Rao,	  C.V.	  2014.	  The	  role	  of	  inflammation	  in	  colon	  cancer.	  Adv	  Exp	  Med	  Biol	  
816:25-­‐52.	  
41.	   Glasner,	  A.,	  Ghadially,	  H.,	  Gur,	  C.,	  Stanietsky,	  N.,	  Tsukerman,	  P.,	  Enk,	  J.,	  and	  Mandelboim,	  O.	  2012.	  
Recognition	  and	  prevention	  of	  tumor	  metastasis	  by	  the	  NK	  receptor	  NKp46/NCR1.	  J	  Immunol	  188:2509-­‐
2515.	  
42.	   Moretta,	  A.,	  Bottino,	  C.,	  Mingari,	  M.C.,	  Biassoni,	  R.,	  and	  Moretta,	  L.	  2002.	  What	  is	  a	  natural	  killer	  cell?	  
Nat	  Immunol	  3:6-­‐8.	  
43.	   Lakshmikanth,	  T.,	  Burke,	  S.,	  Ali,	  T.H.,	  Kimpfler,	  S.,	  Ursini,	  F.,	  Ruggeri,	  L.,	  Capanni,	  M.,	  Umansky,	  V.,	  
Paschen,	  A.,	  Sucker,	  A.,	  et	  al.	  2009.	  NCRs	  and	  DNAM-­‐1	  mediate	  NK	  cell	  recognition	  and	  lysis	  of	  human	  
and	  mouse	  melanoma	  cell	  lines	  in	  vitro	  and	  in	  vivo.	  J	  Clin	  Invest	  119:1251-­‐1263.	  
44.	   Halfteck,	  G.G.,	  Elboim,	  M.,	  Gur,	  C.,	  Achdout,	  H.,	  Ghadially,	  H.,	  and	  Mandelboim,	  O.	  2009.	  Enhanced	  in	  
vivo	  growth	  of	  lymphoma	  tumors	  in	  the	  absence	  of	  the	  NK-­‐activating	  receptor	  NKp46/NCR1.	  J	  Immunol	  
182:2221-­‐2230.	  
45.	   Meresse,	  B.,	  Curran,	  S.A.,	  Ciszewski,	  C.,	  Orbelyan,	  G.,	  Setty,	  M.,	  Bhagat,	  G.,	  Lee,	  L.,	  Tretiakova,	  M.,	  
Semrad,	  C.,	  Kistner,	  E.,	  et	  al.	  2006.	  Reprogramming	  of	  CTLs	  into	  natural	  killer-­‐like	  cells	  in	  celiac	  disease.	  
Journal	  of	  Experimental	  Medicine	  203:1343-­‐1355.	  
46.	   Meresse,	  B.,	  Chen,	  Z.,	  Ciszewski,	  C.,	  Tretiakova,	  M.,	  Bhagat,	  G.,	  Krausz,	  T.N.,	  Raulet,	  D.H.,	  Lanier,	  L.L.,	  
Groh,	  V.,	  Spies,	  T.,	  et	  al.	  2004.	  Coordinated	  induction	  by	  IL15	  of	  a	  TCR-­‐independent	  NKG2D	  signaling	  
pathway	  converts	  CTL	  into	  lymphokine-­‐activated	  killer	  cells	  in	  celiac	  disease.	  Immunity	  21:357-­‐366.	  
47.	   Meresse,	  B.,	  Curran,	  S.A.,	  Ciszewski,	  C.,	  Orbelyan,	  G.,	  Setty,	  M.,	  Bhagat,	  G.,	  Lee,	  L.,	  Tretiakova,	  M.,	  
Semrad,	  C.,	  Kistner,	  E.,	  et	  al.	  2006.	  Reprogramming	  of	  CTLs	  into	  natural	  killer-­‐like	  cells	  in	  celiac	  disease.	  
J	  Exp	  Med	  203:1343-­‐1355.	  
48.	   Tang,	  Q.,	  Grzywacz,	  B.,	  Wang,	  H.,	  Kataria,	  N.,	  Cao,	  Q.,	  Wagner,	  J.E.,	  Blazar,	  B.R.,	  Miller,	  J.S.,	  and	  
Verneris,	  M.R.	  2008.	  Umbilical	  cord	  blood	  T	  cells	  express	  multiple	  natural	  cytotoxicity	  receptors	  after	  IL-­‐
15	  stimulation,	  but	  only	  NKp30	  is	  functional.	  J	  Immunol	  181:4507-­‐4515.	  
49.	   Almeida,	  A.R.,	  Correia,	  D.V.,	  Fernandes-­‐Platzgummer,	  A.,	  da	  Silva,	  C.L.,	  da	  Silva,	  M.G.,	  Anjos,	  D.R.,	  and	  
Silva-­‐Santos,	  B.	  2016.	  Delta	  One	  T	  Cells	  for	  Immunotherapy	  of	  Chronic	  Lymphocytic	  Leukemia:	  Clinical-­‐
Grade	  Expansion/Differentiation	  and	  Preclinical	  Proof	  of	  Concept.	  Clinical	  Cancer	  Research	  22:5795-­‐
5804.	  
50.	   Hudspeth,	  K.,	  Fogli,	  M.,	  Correia,	  D.V.,	  Mikulak,	  J.,	  Roberto,	  A.,	  Della	  Bella,	  S.,	  Silva-­‐Santos,	  B.,	  and	  
Mavilio,	  D.	  2012.	  Engagement	  of	  NKp30	  on	  Vdelta1	  T	  cells	  induces	  the	  production	  of	  CCL3,	  CCL4,	  and	  
CCL5	  and	  suppresses	  HIV-­‐1	  replication.	  Blood	  119:4013-­‐4016.	  
51.	   Allison,	  J.P.,	  Asarnow,	  D.M.,	  Bonyhadi,	  M.,	  Carbone,	  A.,	  Havran,	  W.L.,	  Nandi,	  D.,	  and	  Noble,	  J.	  1991.	  
Gamma	  delta	  T	  cells	  in	  murine	  epithelia:	  origin,	  repertoire,	  and	  function.	  Adv	  Exp	  Med	  Biol	  292:63-­‐69.	  
52.	   Chu,	  C.L.,	  Chen,	  S.S.,	  Wu,	  T.S.,	  Kuo,	  S.C.,	  and	  Liao,	  N.S.	  1999.	  Differential	  effects	  of	  IL-­‐2	  and	  IL-­‐15	  on	  the	  
death	  and	  survival	  of	  activated	  TCR	  gamma	  delta+	  intestinal	  intraepithelial	  lymphocytes.	  J	  Immunol	  
162:1896-­‐1903.	  
53.	   Perera,	  L.,	  Shao,	  L.,	  Patel,	  A.,	  Evans,	  K.,	  Meresse,	  B.,	  Blumberg,	  R.,	  Geraghty,	  D.,	  Groh,	  V.,	  Spies,	  T.,	  
Jabri,	  B.,	  et	  al.	  2007.	  Expression	  of	  nonclassical	  class	  I	  molecules	  by	  intestinal	  epithelial	  cells.	  Inflamm	  
Bowel	  Dis	  13:298-­‐307.	  
54.	   Bloushtain,	  N.,	  Qimron,	  U.,	  Bar-­‐Ilan,	  A.,	  Hershkovitz,	  O.,	  Gazit,	  R.,	  Fima,	  E.,	  Korc,	  M.,	  Vlodavsky,	  I.,	  
Bovin,	  N.V.,	  and	  Porgador,	  A.	  2004.	  Membrane-­‐associated	  heparan	  sulfate	  proteoglycans	  are	  involved	  
in	  the	  recognition	  of	  cellular	  targets	  by	  NKp30	  and	  NKp46.	  Journal	  of	  Immunology	  173:2392-­‐2401.	  
55.	   Hadad,	  U.,	  Thauland,	  T.J.,	  Martinez,	  O.M.,	  Butte,	  M.J.,	  Porgador,	  A.,	  and	  Krams,	  S.M.	  2015.	  NKp46	  
clusters	  at	  the	  immune	  synapse	  and	  regulates	  NK	  cell	  polarization.	  Frontiers	  in	  Immunology	  6.	  
56.	   Glasner,	  A.,	  Levi,	  A.,	  Enk,	  J.,	  Isaacson,	  B.,	  Viukov,	  S.,	  Orlanski,	  S.,	  Scope,	  A.,	  Neuman,	  T.,	  Enk,	  C.D.,	  
Hanna,	  J.H.,	  et	  al.	  2018.	  NKp46	  Receptor-­‐Mediated	  Interferon-­‐gamma	  Production	  by	  Natural	  Killer	  Cells	  
Increases	  Fibronectin	  1	  to	  Alter	  Tumor	  Architecture	  and	  Control	  Metastasis.	  Immunity	  48:107-­‐119	  
e104.	  
57.	   Mayassi,	  T.,	  Ladell,	  K.,	  Gudjonson,	  H.,	  McLaren,	  J.E.,	  Shaw,	  D.G.,	  Tran,	  M.T.,	  Rokicka,	  J.J.,	  Lawrence,	  I.,	  
Grenier,	  J.C.,	  van	  Unen,	  V.,	  et	  al.	  2019.	  Chronic	  Inflammation	  Permanently	  Reshapes	  Tissue-­‐Resident	  
Immunity	  in	  Celiac	  Disease.	  Cell	  176:967-­‐981	  e919.	  
27	  |	  P a g e 	   	   M i k u l a k  J .  e t  a l . 	  
	  
58.	   Pende,	  D.,	  Parolini,	  S.,	  Pessino,	  A.,	  Sivori,	  S.,	  Augugliaro,	  R.,	  Morelli,	  L.,	  Marcenaro,	  E.,	  Accame,	  L.,	  
Malaspina,	  A.,	  Biassoni,	  R.,	  et	  al.	  1999.	  Identification	  and	  molecular	  characterization	  of	  NKp30,	  a	  novel	  
triggering	  receptor	  involved	  in	  natural	  cytotoxicity	  mediated	  by	  human	  natural	  killer	  cells.	  J	  Exp	  Med	  
190:1505-­‐1516.	  
59.	   Ravens,	  S.,	  Schultze-­‐Florey,	  C.,	  Raha,	  S.,	  Sandrock,	  I.,	  Drenker,	  M.,	  Oberdorfer,	  L.,	  Reinhardt,	  A.,	  Ravens,	  
I.,	  Beck,	  M.,	  Geffers,	  R.,	  et	  al.	  2017.	  Human	  gammadelta	  T	  cells	  are	  quickly	  reconstituted	  after	  stem-­‐cell	  
transplantation	  and	  show	  adaptive	  clonal	  expansion	  in	  response	  to	  viral	  infection.	  Nat	  Immunol	  
18:393-­‐401.	  
60.	   Bolotin,	  D.A.,	  Poslavsky,	  S.,	  Mitrophanov,	  I.,	  Shugay,	  M.,	  Mamedov,	  I.Z.,	  Putintseva,	  E.V.,	  and	  
Chudakov,	  D.M.	  2015.	  MiXCR:	  software	  for	  comprehensive	  adaptive	  immunity	  profiling.	  Nat	  Methods	  
12:380-­‐381.	  
61.	   Nazarov,	  V.I.,	  Pogorelyy,	  M.V.,	  Komech,	  E.A.,	  Zvyagin,	  I.V.,	  Bolotin,	  D.A.,	  Shugay,	  M.,	  Chudakov,	  D.M.,	  
Lebedev,	  Y.B.,	  and	  Mamedov,	  I.Z.	  2015.	  tcR:	  an	  R	  package	  for	  T	  cell	  receptor	  repertoire	  advanced	  data	  
analysis.	  BMC	  Bioinformatics	  16:175.	  
62.	   Shugay,	  M.,	  Bagaev,	  D.V.,	  Turchaninova,	  M.A.,	  Bolotin,	  D.A.,	  Britanova,	  O.V.,	  Putintseva,	  E.V.,	  
Pogorelyy,	  M.V.,	  Nazarov,	  V.I.,	  Zvyagin,	  I.V.,	  Kirgizova,	  V.I.,	  et	  al.	  2015.	  VDJtools:	  Unifying	  Post-­‐analysis	  
of	  T	  Cell	  Receptor	  Repertoires.	  PLoS	  Comput	  Biol	  11:e1004503.	  
 
	  
	   	  
N
K
p
3
0
N
K
p
4
4
C
D
4
C
D
8
a
lf
a
C
D
8
b
e
ta
C
D
1
6
C
D
5
6
C
D
6
9
C
D
1
0
3
N
K
G
2
A
N
K
G
2
C
N
K
G
2
D
K
IR
s
2 0
4 0
6 0
8 0
N K p 4 6 neg g d  IE L s
N K p 4 6 p o s g d  IE L s
F
re
q
u
e
n
cy (%
)
**
( 
  
  
) **
( 
  
  
)
*
( 
  
 )
*
( 
  
 ) *
( 
  
 )
***
( 
  
  
  
) ****
( 
  
  
  
  
)
0
5
1 0
1 5
2 5
5 0
7 5
1 0 0
****
*
****
N
C
R
sp
o
s
gd
 T
 c
e
lls
 (
%
)
N K p 4 6 N K p 4 4N K p 3 0
IE L s
L P L s
P B M C s
**
**
****
**
*
0
2 0
4 0
6 0
8 0
1 0 0 **
gd
 /
 C
D
3
p
o
s  
T
 c
e
lls
 (
%
)
C D 8 C D 5 6C D 1 6 N K G 2 A N K G 2 D K IR s
****
****
N K G 2 CC D 4
IE L s
L P L s
P B M C s
**
***
* *
*
G
0
2 0
4 0
6 0
8 0
1 0 0
0
2 0
4 0
6 0
8 0
1 0 0
IE
L s
LP
L s
P B
M
C s
IE
L s
LP
L s
P B
M
C s
C
D
6
9
p
o
s
gd
T
 c
e
lls
(%
)
C
D
1
0
3
p
o
s
gd T
 ce
lls  (%
)
****
****
****
** *
B
A
C
D
FE
H
Mikulak J.	et	al.			Figure	1
0
5
1 0
2 5
5 0
7 5
1 0 0
****
****
gd
/ 
C
D
3
p
o
s  
T
 c
e
lls
 (
%
)
IE
L s
LP
L s
P B
M
C s
0
2 0
4 0
6 0
8 0
1 0 0
N K p 4 6 p o s g d  T o ta l g d
C
D
8p
o
s
gd
 IE
Ls
 (
%
) *
C D 8a
C D 8 b
*
0 50K 100K 150K 200K 250K
0
50K
100K
150K
200K
250K
0 50K 100K 150K 200K 250K
0
102
103
104
105
0 102 103 104 105
0
50K
100K
150K
200K
250K
0102 103 104 105
0
102
103
104
105
0102 103 104 105
0
102
103
104
105
58%
FS
C-
A
0
0
SSC-A
0 50K 100K 150K 200K 250K
0
50K
100K
150K
200K
250K
0 50K 100K 150K 200K 250K
0
102
103
104
105
0 102 103 104 105
0
50K
100K
150K
200K
250K
0102 103 104 105
0
102
103
104
105
0102 103 104 105
0
102
103
104
105
43%
gd T
SS
C-
A
0
0
0 50 100 150 200K 250K
0
50K
100K
150K
200K
250K
0 50K 100K 150K 200K 250K
0
102
103
104
105
0 102 103 104 105
0
50K
100K
150K
200K
250K
0102 103 104 105
0
102
103
104
105
0102 103 104 105
0
102
103
104
105
36%
CD3
CD
45
0
0 50K 100K 150K 200K 250K
0
50K
100K
150K
200K
250K
0 50K 100K 150K 200K 250K
0
102
103
104
105
0 102 103 104 105
0
5 K
100K
150K
200K
250K
0102 103 104 105
0
102
103
104
105
0102 103 104 105
0
102
103
104
105
57%
FSC-H
FS
C-
A
0
0 5 0 150 2 2
0
50K
100K
150K
200K
250K
0 5 100K 150K 2 2
0
102
103
104
105
0 102 3 4 105
0
50K
100K
150K
200K
250K
0102 103 104 105
0
102
103
104
105
0102 103 104 105
0
102
103
104
105
80%
FSC-A
Zo
m
bi
e 0
0 103 104105
010
2
103
104
105
0 103 104105
010
2
103
104
105
0102 103104105
0
102
103
104
105
CD8a
CD
8b 8%
92%
0 103 104105
010
2
103
104
105
0 103 104105
010
2
103
104
105
0102 103104105
0
102
103
104
105
CD8a
CD
8	
b 58%
42%
tSNE_1/2
tS
N
E
_2
/2
tSNE_1/2
0 50 100 150 200 250
tSNE C4_CD3+CD45+ 1/2
0
50
100
150
200
250
tS
N
E 
C
4_
C
D
3+
C
D
45
+ 
2/
2
Gate
CD45+CD3+
NKp46+
NKp46-
CD45posCD3pos
NKp46pos gd IELs	(C2)		
NKp46neg gd IELs	(C1)	
0 50 100 150 200 250
tSNE C2_gdTCR 1/2
0
50
100
150
200
250
tS
N
E 
C
2_
gd
TC
R
 2
/2
Gate
NKp46+
NKp46-
tS
N
E
_2
/2
Figure 1. 
Identification of a novel subset of NKp46pos intraepithelial Vd1 T lymphocytes highly enriched in 
human healthy intestine. 
(A) Representative example of flow cytometry dot plots showing the gating strategy used to identify 
viable CD45pos/CD3pos gd T lymphocyte both in intraepithelial (IEL) and lamina propria (LPL) 
compartments from specimens of human healthy colon. (B) Summary statistical graph showing within 
the CD45pos/CD3pos lymphocytes the percentages of gd IELs (N=54 in white circles), gd LPLs (N=20 
in gray circles) from human healthy colon specimens and gd peripheral blood mononuclear cells 
(PBMCs) (N=26 in black circles) of healthy donors. (C) Summary statistical graph showing the 
expression (%) of CD69 (left) and CD103 (right) on gd IELs (N=20 in white circles), gd LPLs (N=15 
in grey circles) from specimens of human healthy colon and on gd T cell from PBMCs (N=20 in black 
circles) of healthy donors. (D) Summary statistical graph showing the expression (%) of CD4, CD8, 
CD16, CD56, NKG2A, NKG2C, NKG2D and Killer Immunoglobulin-like Receptors (KIRs) on gd 
IELs (N ≥13 in white circles), gd LPLs (N ≥10 in gray circles) from specimens of human healthy colon 
and on gd T cells from PBMCs of healthy donors (N ≥13 in black circles). (E) Summary statistical 
graph showing the expression (%) of NKp46, NKp30 and NKp44 on gd IELs (N ≥25 in white circles), 
gd LPLs (N ≥16 in gray circles) from specimens of human healthy colon and on gd T cells from 
PBMCs from healthy donors (N ≥25 in black circles). (F) Summary statistical analysis (upper graph) 
showing the expression (%) of CD8a (white circles) and CD8b (black circles) chains within the CD8 
receptor of matched CD8pos gd IELs and CD8pos/NKp46pos gd IELs from specimens of human healthy 
colon (N=15). White arrows indicate representative flow cytometry dot plots showing co-expression of 
CD8a and CD8b chains respectively in CD8pos total gd T (left) or NKp46pos/gd T (right) IELs. (G) t-
SNE graphs from a representative specimen of human healthy colon showing the clustering of 
NKp46neg (C1 in blue) and NKp46pos (C2 in orange) gd IELs within CD45pos /CD3pos lymphocytes 
(gray; left panel) or in gd T IELs (right panel). (H) Heat-map graph showing the degree of expression 
of several surface markers on matched NKp46neg and NKp46pos gd IELs clusters defined as C1 and C2 
in panel G (N=7).  
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Figure 2. 
NKp46pos gd IELs are Vd1 restricted and express a cytotoxic phenotype. 
(A) Summary statistical graphs (upper line) showing within the entire CD45pos/CD3pos lymphocyte 
population the percentages of Vd1 or Vd2 IEL (N=37) and LPL (N ≥22) subsets from specimens of 
human healthy colon and from PBMCs (N=49) of healthy donors. Data are represented as scattered 
plots of paired observations. Pie charts (lower line) showing the percentages of Vd1pos, Vd2pos and 
Vd1neg/Vd2neg   subsets within total gd T cells of matched samples (N=10) of IELs and LPLs from 
specimens of human healthy colon and PBMCs of healthy donors. (B) Representative examples  (out 
of 38) of contour plots showing the percentages of Vd1pos and Vd2pos T cell subset (upper panel) and of 
NKp46pos/Vd1 T cells (lower panel) within total purified gd IELs from a specimen of human healthy 
colon. (C) Summary statistical graph showing the frequencies of Vd1 (white circles) and Vd2 (black 
circles) IELs (N ≥20) from specimens of human healthy colon expressing NKp46, NKp44 and NKp30. 
(D) Summary statistical graph showing the frequencies of Vd1 (white circles) and Vd2 (black circles) 
IELs (N ≥16) from specimens of human healthy colon expressing CD4, CD8, CD16, CD56, NKG2A, 
NKG2D and Killer Immunoglobulin-like Receptors (KIRs).  
	

	
	
Figure 3. 
TCR repertoires of NKp46pos and NKp46neg γδ IELs.  
(A) Treemap graphs showing the distribution of TRG clones within NKp46pos and NKp46neg γδ IELs 
from two representative patients (out of 4). Squares represent individual clones and are proportional to 
the abundance of the given clone within the TCR repertoire. Color codes indicate V-chain usage. 
CDR3 sequences of the most expanded clones are given. (B) Dot plot graph showing the quantification 
of V-chains for TRG repertoires. Each dot represents one patient. (C) Treemap graphs showing the 
distribution of Vδ1pos TRD clones within NKp46pos and NKp46neg IELs of two patients. Each square 
indicates one clone within the given TRD repertoires. J-elements are color coded and CDR3 sequences 
of the most expanded clones are indicated. (D) Dot plot graph showing the TRG and TRD diversity 
that is determined by the D50 score (number of clones within 50% of the given TCR repertoire). Each 
dot represents one patient. (E) Heatmap graph displaying the number of shared TRG (lower part, 
orange - yellow) and TRD (upper part, blue - yellow) clones between patients’ samples.  

Figure 4. 
Effector-functions of NKp46pos gd IELs. 
(A) Summary statistical graphs showing the transcript levels of NKp46, IL-10, IL-17, IL-22, TGF-
b, and lymphotactin/XCL1 and in FACS-sorted NKp46pos and NKp46neg gd IELs from specimens of 
human healthy colon (N=6) and in FACS-sorted gd T cell from PBMCs of healthy donors (N=6). 
Results are presented as fold changes (2-DDCT) of target gene relative to PBMC samples and normalized 
to housekeeping genes GAPDH and S18. (B-D) Summary statistical graphs showing the intracellular 
levels of IFN-g (B), Granzyme B (GMZB) (C) and surface expression of CD107a (D) by NKp46pos and 
NKp46neg gd IELs from specimens of human healthy colon either in the absence (Ctrl) or in the 
presence of K562 cell lines. (E) Summary statistical graphs showing the surface expression of CD107a 
by NKp46pos gd IELs from healthy colon either alone or in co-culture with tumor target cells SKCO1 
(left) and Caco2 (right). (F) Summary statistical graph showing the surface expression of CD107a by 
NKp46pos gd IELs from healthy colon after co-culture with K562 either in the absence or presence of a 
blocking anti-NKp46 IgM mAb (N=7).  
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Figure 5. 
NKp46pos/Vd1 T cell expansion following activation of thymocyte precursors with IL-2 or IL-15. 
(A) Summary statistical graphs showing the time course expression of NKp46 in gd thymocyte 
precursors (N ≥5) cultured with IL-2 (200 U/mL) or IL-15 (10 ng/mL) or IL-7 (10 ng/mL). (B) 
Summary statistical graphs showing the frequencies of Vd1 (left graph) and Vd2 (right graph) 
thymocytes cultured either in absence (Ctrl) or presence of IL-2 for 6 days (N=10). Data are 
represented as scattered plots of paired observations. (C) Summary statistical graphs showing the 
frequency of NKp46 expression on Vd1 thymocytes cultured either in the absence (Ctrl) or in the 
presence of IL-2 for 6 days (N=10). (D) Summary statistical graphs showing NCR expression in gd 
and ab thymocytes as well as in gd T cells from PBMCs of healthy donor cultured either in absence 
(Ctrl) or in the presence of IL2 for 6 days (N ≥5).  
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Figure 6. 
Phenotype and functions of human of NKp46pos gd thymocyte precursors following activations 
with physiologic and pathologic stimuli.  
(A) Summary statistical graphs showing the expression of CD4, CD8, CD56, NKG2A, NKG2D, 
CD16 and CCR9 on gd thymocyte precursors (N ³ 8) cultured either in the absence (Ctrl) or presence 
of IL-2. (B) Summary statistical graphs showing the CCL25 dose-dependent chemotaxis of FACS-
sorted CCR9pos/NKp46pos Vd1 T cells generated from thymocyte precursors cultured with IL-2 for 6 
days (N=8). (C) Summary statistical graphs showing the transcripts levels of GZMB and NKp46 
transcripts on freshly FACS-sorted thymocytes (Ctrl) and on NKp46pos and NKp46neg Vd1 T cells 
generated from thymocyte precursors cultured with IL-2 for 6 days (N=6). Results are represented as 
the fold change (2-DDCT) of target gene relative to a Ctrl samples and normalized to housekeeping genes 
GAPDH and S18. (D) Summary statistical graphs showing the expression of CD107a on NKp46pos and 
NKp46neg Vd1 T cells generated from thymocyte precursors cultured with IL-2 for 6 days either in the 
absence (Ctrl) or in the presence of K562 or Caco2 human tumor target cells (N ³ 9). (E) Summary 
statistical graphs showing the NKp46 expression on freshly purified thymocytes (Day 0) and on gd 
thymocytes cultured with IL-2 for 6 days either in the absence (Ctrl) or in the presence of primary 
human colonic epithelial cells (HCoEpic) or IL-15 or TGF-b or Caco2 cell line (N ³ 8).  
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Figure 7. 
Clinical relevance of the NKp46pos/Vd1 subset in the pathogenesis of CRC. 
(A-D) Summary statistical graphs showing the frequencies of total gd (A), Vd1 and Vd2 (B), 
NKp46pos/Vd1 (C) and NKp46pos/Vd2 (D) IEL subsets in healthy intestinal specimens from CRC 
patients in early (I-II) and late (III-IV) disease stages (N ³17). (E-F) Summary statistical graphs 
showing the frequencies of total Vd1 cells (E) and of the NKp46pos/Vd1 T cell subset (F) in both IELs 
and LPLs compartments of healthy/disease-free intestine compared to those of infiltrating gut 
specimens of colon rectal cancer (CRC) (N ³ 15). 
 
 
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
